Press Release Apr 26 2021
Filed with NSE · · 2 pages · English
Summary by 6ix AI
The company is seeking approval from the Central Drugs Standard Control Organization for a Phase-III clinical trial of the drug. NATCO believes that the drug could be approved for compassionate use, allowing access for patients with life-threatening conditions. If approved, NATCO is prepared to launch the product within the month.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Earlier from NATCO Pharma
- NATCO Pharma receives tentative approval for Ibrutinib tablets (generic for IMBRUVICA) ANDA in the US market
- Press Release Apr 10 2021
- NATCO Pharma forays into Pheromone based technology for Integrated Pest Management
- Press Release Mar 15 2021
- Press Release Mar 08 2021
Later from NATCO Pharma
- Press Release May 03 2021
- Press Release May 17 2021
- Press Release May 21 2021
- Press Release May 22 2021
- Press Release Jun 14 2021
Follow NATCO Pharma into a list and get an email when it puts out news.
Follow NATCO Pharma